Photo by ldxcreative from unsplash
Treatment with immune checkpoint inhibitors (ICIs) is frequently associated with immune‐related adverse events (irAEs). A new study identified an interleukin 7 (IL‐7) allelic variant—rs16906115—as a major risk factor for the… Click to show full abstract
Treatment with immune checkpoint inhibitors (ICIs) is frequently associated with immune‐related adverse events (irAEs). A new study identified an interleukin 7 (IL‐7) allelic variant—rs16906115—as a major risk factor for the development of ICI‐associated irAEs. This association is of great significance as it indicates that germline genetic variants influence the occurrence of irAEs, thus opening a new avenue for identifying high‐risk patients to enable better management of ICI therapy and associated irAEs.
Journal Title: Molecular Oncology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!